Eisai Newsroom http://eisai.mediaroom.com/ Eisai Newsroom Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma http://eisai.mediaroom.com/2018-05-24-Eisai-And-Merck-Provide-Update-on-Supplemental-New-Drug-Application-sNDA-for-Lenvatinib-in-First-Line-Unresectable-Hepatocellular-Carcinoma Thu, 24 May 2018 19:34:00 -0400 http://eisai.mediaroom.com/2018-05-24-Eisai-And-Merck-Provide-Update-on-Supplemental-New-Drug-Application-sNDA-for-Lenvatinib-in-First-Line-Unresectable-Hepatocellular-Carcinoma Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting http://eisai.mediaroom.com/2018-05-22-Eisai-and-Purdue-Pharma-Announce-Key-Phase-1-Clinical-Studies-of-Lemborexant-to-be-Presented-at-the-32nd-Annual-SLEEP-Meeting Tue, 22 May 2018 09:30:00 -0400 http://eisai.mediaroom.com/2018-05-22-Eisai-and-Purdue-Pharma-Announce-Key-Phase-1-Clinical-Studies-of-Lemborexant-to-be-Presented-at-the-32nd-Annual-SLEEP-Meeting Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy Under Strategic Oncology Collaboration with Merck http://eisai.mediaroom.com/2018-05-17-Eisai-Announces-Data-at-ASCO-2018-Annual-Meeting-Showcasing-LENVIMA-R-lenvatinib-and-KEYTRUDA-R-pembrolizumab-Combination-Therapy-Under-Strategic-Oncology-Collaboration-with-Merck - Data highlights continued investigation of LENVIMA as monotherapy and in combination with Merck's KEYTRUDA across multiple cancer types under global collaboration to co-develop and co-commercialize LENVIMA Thu, 17 May 2018 08:08:00 -0400 http://eisai.mediaroom.com/2018-05-17-Eisai-Announces-Data-at-ASCO-2018-Annual-Meeting-Showcasing-LENVIMA-R-lenvatinib-and-KEYTRUDA-R-pembrolizumab-Combination-Therapy-Under-Strategic-Oncology-Collaboration-with-Merck Eisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA http://eisai.mediaroom.com/2018-04-19-Eisai-presentations-at-the-Annual-Meeting-of-the-American-Academy-of-Neurology-highlight-key-data-supporting-real-world-retention-rates-and-long-term-seizure-freedom-rates-with-FYCOMPA Abstracts presented add to growing body of FYCOMPA data supporting convulsive seizure freedom, and real-world, long-term safety & efficacy data Thu, 19 Apr 2018 10:00:00 -0400 http://eisai.mediaroom.com/2018-04-19-Eisai-presentations-at-the-Annual-Meeting-of-the-American-Academy-of-Neurology-highlight-key-data-supporting-real-world-retention-rates-and-long-term-seizure-freedom-rates-with-FYCOMPA Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA® (perampanel) Pediatric Indications http://eisai.mediaroom.com/2018-03-30-Eisai-Submits-Supplemental-New-Drug-Application-sNDA-to-FDA-for-FYCOMPA-R-perampanel-Pediatric-Indications - First step to making FYCOMPA available for children, underscoring Eisai's commitment to epilepsy care for patients of all ages Fri, 30 Mar 2018 14:52:00 -0400 http://eisai.mediaroom.com/2018-03-30-Eisai-Submits-Supplemental-New-Drug-Application-sNDA-to-FDA-for-FYCOMPA-R-perampanel-Pediatric-Indications